Table 2 EBMT disease indications—(a) adults and (b) paediatrics

Disease	Sibling donor	Well-matched unrelated ^a	Autologous
(a)
MS	D/III	GNR/III	CO/II
SSc	D/III	GNR/III	CO/II
SLE	D/III	GNR/III	CO/II
Crohn's	GNR/III	GNR/III	CO/II
RA	GNR/III	GNR/III	CO/II
Vasculitis	GNR/III	GNR/III	CO/II
Polymyositis–dermatomyositis	GNR/III	GNR/III	CO/II
CIPD	GNR/III	GNR/III	CO/II
NMO	GNR/III	GNR/III	CO/II
Cytopenia	CO/II	D/III	CO/II
T1D	GNR/III	GNR/III	D/III
RCD II	GNR/III	GNR/III	D/III
(b)
JIA	D/III	GNR/III	CO/II
JSSc	D/III	GNR/III	CO/II
JSLE	D/III	GNR/III	CO/II
Crohn's	GNR/III	GNR/III	CO/II
Vasculitis	GNR/III	GNR/III	CO/II
Polymyositis–dermatomyositis	GNR/III	GNR/III	CO/II
Cytopenia	CO/II	CO/II	CO/II
T1D	GNR/III	GNR/III	D/III

Abbreviations: CIPD=chronic inflammatory demyelinating polyradiculoneuropathy; EBMT=European Group for Blood and Marrow Transplantation; JIA=juvenile chronic arthritis; JSLE=juvenile systemic lupus erythematosus; JSSc=juvenile systemic sclerosis; MS=multiple sclerosis; NMO=neuromyelitis optica; T1D=type 1 diabetes; RA=rheumatoid arthritis; RCD II=refractory type II coeliac disease; SSc=systemic sclerosis; SLE=systemic lupus erythematosus.
^aA well-matched unrelated donor is defined as a 9/10 or 10/10 identical donor based on HLA high-resolution typing for class I (HLA-A, -B, -C) and II (HLA-DRB1, DQB1).
EBMT grades of evidence:⁷⁸ I=evidence from at least one well-executed randomized trial; II=evidence from at least one well-designed clinical trial without randomization: cohort or case-controlled analytical studies (preferably from more than one centre), multiple time-series studies: or dramatic results from uncontrolled experiments; III=evidence from opinions of respected authorities based on clinical experience, descriptive studies or reports from expert committee.
EBMT grades of recommendation:⁷⁸ CO=Clinical Option: can be carried out after careful assessment of risks and benefits; D=developmental; GNR=generally not recommended; S=standard: generally indicated in suitable patients.

Search